LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LYEL
Lyell Immunopharma, Inc.
There isn't enough reported data to score LYEL yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LYEL Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
LYEL's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LYEL PE Valuation
LYEL has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LYEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect LYEL's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LYEL on earnings quality, reporting a profit while its opponent remains loss making.
LYEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.32 | +$10.70 |
| Q2 2026 | -$12.59 | +$11.70 |
| Q1 2026 | -$13.56 | +$11.44 |
| Q4 2025 | -$16.06 | +$10.14 |
| Q3 2025 | -$23.02 | -$7.22 |
| Q2 2025 | -$24.29 | -$7.89 |
| Q1 2025 | -$25.00 | -$7.00 |
| Q4 2024 | -$26.20 | -$7.60 |
LYEL is still losing money, but far less than before: $12.32 per share over the past year, against $26.20 at its worst in late 2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LYEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LYEL on profitability, with a higher operating margin.
LYEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3K | -80% |
| Q2 2026 | $4K | -50% |
| Q1 2026 | $2K | -71% |
| Q4 2025 | $6K | -45% |
| Q3 2025 | $15K | -56% |
| Q2 2025 | $8K | -38% |
| Q1 2025 | $7K | +133% |
| Q4 2024 | $11K | -15% |
LYEL's revenue has slid since its 2022 peak: $3,000 last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1609833% | -1361480 points |
| Q2 2026 | -1183425% | -594175 points |
| Q1 2026 | -2213050% | -1393521 points |
| Q4 2025 | -2127400% | -298791 points |
| Q3 2025 | -248353% | -99809 points |
| Q2 2025 | -589250% | -192881 points |
| Q1 2025 | -819529% | +1032971 points |
| Q4 2024 | -1828609% | -1370855 points |
LYEL's operating margin was −1609833% last quarter, down 1361480 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LYEL on cash generation, producing positive trailing cash flow while its opponent burns cash.
LYEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.6M | -$6M |
| Q2 2026 | -$34.2M | +$448K |
| Q1 2026 | -$38.6M | +$16.4M |
| Q4 2025 | -$32.6M | +$14.7M |
| Q3 2025 | -$28.6M | +$6.5M |
| Q2 2025 | -$34.6M | +$3.8M |
| Q1 2025 | -$55M | -$12.9M |
| Q4 2024 | -$47.3M | -$6.6M |
LYEL has burned cash in almost every quarter: −$140M over the past year, against −$166M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LYEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LYEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +1.1M shares |
| 1 year | +65% | +9.6M shares |
| 3 years | +95% | +11.9M shares |
| 5 years | +105% | +12.5M shares |
LYEL has 24M diluted shares, up 65% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $11.8M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LYEL Net Leverage
LYEL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LYEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.4 | Neutral |
| Stochastic | 65.6 | Neutral |
LYEL's weekly RSI is 55 (neutral) and its Stochastic is 66 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LYEL PE vs Healthcare Sector
LYEL has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LYEL on trend strength, trading above more of its moving averages.
LYEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 44% above |
| 20 week MA | $12.5 | 25% above |
| 50 week MA | $18.3 | 14% below |
| 100 week MA | $15.3 | 2.2% above |
| 200 week MA | $28.4 | 45% below |
LYEL's trend is mixed: it's above three of its five weekly moving averages, and 45% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LYEL on returns for 2026, with the stronger performance.
LYEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $324.0 | $164.2 | -49% |
| 2022 | $164.2 | $61.0 | -63% |
| 2023 | $61.0 | $38.8 | -36% |
| 2024 | $38.8 | $13.0 | -66% |
| 2025 | $13.0 | $35.1 | +170% |
| 2026 YTD | $35.1 | $15.6 | -55% |
LYEL's yearly returns have swung widely, from +170% in 2025 to −66% in 2024. It's down 55% so far in 2026.